Shreya Agrawal: Integrated Risk Scores for Thrombosis and Bleeding
Shreya Agrawal, Consultant Hematologist and Bone marrow transplant physician at S. L. Raheja Hospital – A Fortis Associate, shared a post on LinkedIn:
“In hematology and cardiology practice, risk stratification is everything.
We often talk about thrombosis and bleeding as separate problems — but in reality, they coexist in a delicate balance.
The real art lies in identifying who needs prolonged anticoagulation, who needs dual antiplatelet therapy, and who is at high bleeding risk.
There are several validated tools that help us move from instinct-based decisions to evidence-based precision:
- VTE recurrence after anticoagulation – Vienna, HERDOO2
- Bleeding risk on OAC – VTE-BLEED, CHAP
- Post-PCI risk stratification – DAPT score, PRECISE-DAPT
- PAD and cardiovascular risk – OAC3-PAD, SMART
- Diabetes and 10-year CV risk – SCORE2
Each tool incorporates clinical variables we routinely assess — age, renal function, hemoglobin, prior bleeding, inflammatory markers, comorbidities — but converts them into structured decision support.
Why this matters:
- Avoid unnecessary prolonged anticoagulation
- Identify patients who truly benefit from extended therapy
- Reduce preventable bleeding
- Personalize cardiovascular prevention
As we move toward precision medicine, structured risk calculators are no longer optional — they’re essential.
Curious to know — how many of these scores are you actively using in daily practice?”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS